Evidence map›Paper›PMID 38722709›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2024

Validation of the Onset of Effect Questionnaire in Participants With Chronic Obstructive Pulmonary Disease.

Charlie Strange, Barry J Make, Frank J Trudo, Gale Harding, Danielle Rodriguez, James M Eudicone, Norbert Feigler, Hitesh N Gandhi

Abstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charlie StrangeDivision of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina, United States.
Barry J MakeDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, United States.
Frank J TrudoBioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.
Gale HardingEvidera, Bethesda, Maryland, United States.
Danielle RodriguezEvidera, Seattle, Washington, United States.
James M EudiconeBioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.
Norbert FeiglerBioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.
Hitesh N GandhiAlexion, AstraZeneca Rare Disease, Wilmington, Delaware, United States.

Funding

AstraZeneca
6 · The paper itself

Abstract

Background: Patient perception of medication onset of effect is important for adherence. Although the Onset of Effect Questionnaire (OEQ) has been validated in patients with asthma, it has not been evaluated in patients with chronic obstructive pulmonary disease (COPD). This study evaluated the COPD-OEQ in patients with COPD. Methods: Two analyses (qualitative and quantitative) were conducted to assess the content validity and psychometric properties of the COPD-OEQ in participants with COPD. In the qualitative analysis, interviews assessed content validity by concept elicitation (CE) and cognitive interviewing (CI). CE included questions to understand patient experience related to onset of medication effect. CI included completion of the COPD-OEQ and assessment of the COPD-OEQ items, response options, and instructions. During the 2-week quantitative analysis, 2 versions of the COPD-OEQ (Weekly and Daily) were administered to assess test-retest reliability, construct validity, and known-groups validity. Results: The qualitative analysis demonstrated that 3 of the 5 COPD-OEQ items were relevant and understood as intended. Qualitative findings demonstrated inconsistent evidence that the COPD-OEQ Weekly and Daily were reliable and valid measures in participants with COPD. Test-retest reliability was observed for the COPD-OEQ Weekly and Daily; however, construct validitywas weak and demonstrated inconsistent correlations among COPD-OEQ items. Overall, known-groups validity was not demonstrated. Conclusion: The weak evidence from the quantitative analysis of the COPD-OEQ Weekly and Daily tools does not support use of the OEQ in general COPD. The study supports the content validity for the assessment of perceived onset of effect in patients with COPD.

Indexed as

chronic obstructive pulmonary diseaseOnset of Effect Questionnairepatient-reported outcome

Identifiers

PMID38722709
PMCPMC11363968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.